Change in Negative Affective Bias following a Single Ketamine Treatment for Treatment-Resistant Depression
Anna J. Harvey, Stevan Nikolin, Nicholas Chand, William Flanney, Liyi Tan, Adriano Moffa, Colleen K. Loo, Donel M. Martin
Depression and Anxiety August 19, 2023 Peer reviewed DOI: 10.1155/2023/3371272
Summary
A single treatment of ketamine improved negative processing bias in participants with treatment-resistant major depressive disorder, as shown by a significant result on the Scrambled Sentence Task (Cohen’s d = .67). However, no significant changes were observed in most emotional and cognitive processing tasks. The improvement in negative bias was not strongly linked to overall psychological symptom relief. Limitations include a small sample size and no follow-up assessments.
Study at a glance
| Design | randomised double-blind controlled study |
|---|---|
| Sample size | 44 |
| Population | participants with treatment-resistant major depressive disorder and healthy controls |
| Key finding | Ketamine treatment improved negative processing bias but did not significantly affect other emotional or cognitive measures. |
Abstract
Ketamine has recently emerged as a highly effective new treatment for people with treatment-resistant depression with rapid antidepressant effects. However, these effects are often short lasting, and the potential cognitive mechanisms underlying the therapeutic effects, such as effects on emotional processing bias, remain poorly understood. In the present study, we explored potential changes in emotional and cognitive processing following a single treatment of subcutaneous ketamine in a randomised double-blind controlled study with an active control. Participants with treatment-resistant major depressive disorder (MDD) were recruited from a single site from the Ketamine for Adult Depression Study (KADS Trial) and were randomly assigned to receive racemic ketamine hydrochloride ( n = 10 ) or midazolam hydrochloride ( n = 11 ) in a 1 : 1 ratio. A healthy control sample ( n = 23 ) was recruited to attend a single experimental session without any treatment. All MDD participants completed mood ratings and cognitive assessments prior to and one day after a single randomised treatment. The results showed no significant differences in performance changes after treatment across the majority of emotion-related (i.e., Emotional Stroop Task, Affective Go/No-Go Task) and cognitive (Ruff 2 and 7 Selective Attention Test, Controlled Word Association Test) outcome measures. Participants who received ketamine showed a significant improvement in a negative processing bias test (i.e., The Scrambled Sentence Task; Cohen’s d = .67 , p = .016 ), which was not significantly associated with improvement in psychological symptoms ( r = − .662 , p = .074 ). The results from this exploratory study suggest that a single ketamine treatment may modulate negative affective bias. Limitations to this study included the small sample size and lack of follow-up. Future larger trials are required to confirm this finding.